Back to speakers


Professor of Medicine, Lyon University, Institut Universitaire de France // Medical Director, Hepatology Department at the Hospices Civils de Lyon, France // Scientific Director, Viral Hepatitis Research Laboratory, INSERM U1052, Cancer Research Center of Lyon, France


City: Lyon

Institution: Lyon University and INSERM

Biography of Fabien ZOULIM

Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and as head of the clinical viral hepatitis study section at ANRS. He served as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research. He has been the scientific coordinator of a European Community-funded Network of Excellence on the management of antiviral drug resistance. He is currently coordinating the ANRS “HBV cure” program in France and the IP-cure-B project within the EU H2020 workprogram. He co-founded the International Coalition to Eliminate HBV (ICE-HBV: http// Fabien Zoulim is a recognized expert in the field of viral hepatitis and antiviral therapy, and has published more than 400 articles (H index 75, Web of Science).

PHC's participations

Monday, March 27th 2023

New drugs for HBV cure -

Tuesday, March 09th 2021

International review of the delta through a clinical case

Monday, March 08th 2021

New drugs for HBV cure -

13th PHC – 2020

Monday, January 13th 2020

Can we cure HBV with novel direct acting antivirals? -

Tuesday, January 14th 2020

LUNCH WORKSHOPS - 2. Management of hepatitis delta in 2020*: Room 243 (chairman)

12th PHC – 2019

Tuesday, January 15th 2019

CONTROVERSY - To stop or not to stop NUCs? (chairman)

1st PHC – 2004

Saturday, September 11th 2004

Clinical Virology of Hepatitis B (chairman) -

2nd PHC – 2007

Tuesday, January 23rd 2007

How to use virological tools for the optimal management of chronic hepatitis B -

3rd PHC – 2009

Tuesday, January 20th 2009

How to prevent, diagnose and overcome resistance under nucleos(t)ide analogs ? -

4th PHC – 2011

Tuesday, January 18th 2011

Is resistance disappearing? -

5th PHC – 2012

Tuesday, January 31st 2012

Response unguided or guided ? (chairman) -

Interactive Luncheons - Room 4 -

6th PHC – 2013

Tuesday, January 15th 2013

Optimal management of patients with resistance -

7th PHC – 2014

Tuesday, January 14th 2014

The control of HBV related liver disease (chairman)

11th PHC – 2018

Tuesday, January 16th 2018

How to improve access to therapy for HBV patients? -

10th PHC – 2017

Tuesday, January 31st 2017

New targets for HBV therapies -

8th PHC – 2015

Tuesday, January 13th 2015

The control of HBV related liver disease (chairman)

9th PHC – 2016

Tuesday, January 12th 2016

What's new in hepatitis B? (chairman)

Clinical relevance of HBV cccDNA -

Lunch Workshops - Room 252B (chairman)